Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed its forecast and conducted a sum-of-the-parts analysis. The investor debate is shifting towards ALKS 2680, which will gain greater attention into the Phase 2 readouts in the second half of 2025, given its potential to be disruptive in the $10B branded narcolepsy and idiopathic hypersomnia markets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALKS:
- Biotech Alert: Searches spiking for these stocks today
- Stifel bullish on orexin, upgrades Alkermes to Buy
- Alkermes upgraded to Buy from Hold at Stifel
- Alkermes price target lowered to $28 from $29 at BofA
- Alkermes price target lowered to $43 from $48 at Cantor Fitzgerald
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
